Log In
Print
BCIQ
Print
Print this Print this
 

SCY-635

  Manage Alerts
Collapse Summary General Information
Company Scynexis Inc.
DescriptionNon-immunosuppressive cyclophilin inhibitor
Molecular Target Cyclophilin
Mechanism of ActionCyclophilin inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection in treatment-naïve patients; Treat HCV infection
Regulatory Designation
Partner Waterstone Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$5.5M

$1.0M

$4.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today